2020
DOI: 10.1038/s41386-020-00927-x
|View full text |Cite
|
Sign up to set email alerts
|

Facilitating mGluR4 activity reverses the long-term deleterious consequences of chronic morphine exposure in male mice

Abstract: doi: bioRxiv preprint Background: Understanding the neurobiological underpinnings of abstinence from drugs of abuse is critical to allow better recovery and ensure relapse prevention in addicted subjects. Methods: By comparing the long-term transcriptional consequences of morphine and cocaine exposure, we identified the metabotropic glutamate receptor subtype 4 (mGluR4) as a promising pharmacological target in morphine abstinence. We evaluated the behavioral and molecular effects of facilitating mGluR4 activit… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
22
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6
1

Relationship

2
5

Authors

Journals

citations
Cited by 11 publications
(24 citation statements)
references
References 127 publications
2
22
0
Order By: Relevance
“…or per os, in a volume of 20 ml/kg – except for combination with VU0155041: 10 mg/kg) or acutely (250 mg/kg, 20 ml/kg), KBr (Sigma-Aldrich, Saint-Quentin Fallavier, France; 145 mg/kg; i.p., 20 ml/kg), bumetanide (R&D systems, Minneapolis, USA, 0.5 and 2 mg/kg; i.p., 20 ml/kg) or VU0155041 (Cayman Chemical, Ann Arbor, USA, once a day, i.p., 1 mg/kg, 10 ml/kg). Doses of bumetanide were chosen based on previous studies in rodent models of ASD ( 40, 74 ); liminal dose of VU0155041 was set based on our previous studies ( 51, 100 ) and a pilot experiment showing no detectable effect in the social interaction test. When treatment was given chronically, behavioral testing started 8 days after beginning of daily administration.…”
Section: Methodsmentioning
confidence: 99%
See 3 more Smart Citations
“…or per os, in a volume of 20 ml/kg – except for combination with VU0155041: 10 mg/kg) or acutely (250 mg/kg, 20 ml/kg), KBr (Sigma-Aldrich, Saint-Quentin Fallavier, France; 145 mg/kg; i.p., 20 ml/kg), bumetanide (R&D systems, Minneapolis, USA, 0.5 and 2 mg/kg; i.p., 20 ml/kg) or VU0155041 (Cayman Chemical, Ann Arbor, USA, once a day, i.p., 1 mg/kg, 10 ml/kg). Doses of bumetanide were chosen based on previous studies in rodent models of ASD ( 40, 74 ); liminal dose of VU0155041 was set based on our previous studies ( 51, 100 ) and a pilot experiment showing no detectable effect in the social interaction test. When treatment was given chronically, behavioral testing started 8 days after beginning of daily administration.…”
Section: Methodsmentioning
confidence: 99%
“…When assessing effects of chronic administration, experiments were performed successively (timelines in Fig. 1, 4 and 5) ( 51, 100 ). Testing order was chosen to minimize the incidence of anxiety on later assays.…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…Cocaine use in rats increased the expression of both mGlu4 and mGlu7 within the hippocampus and NAc while decreasing expression in the amygdala 419 . Within mice, however, mGlu4 expression was unchanged in both the NAc and CPu following cessation from cocaine administration 420 , again raising questions regarding whether these alteration are species-specific, or model-specific, effects. In rat models of self-administration, systemic administration of the agonist LSP2-9166 or the mGlu4-specific PAM Lu AF21934 decreased sensitization to cocaine 419,421 .…”
Section: Addictionmentioning
confidence: 99%